Protiva Biotherapeutics this week filed two separate lawsuits against one-time parent company Inex Pharmaceuticals and erstwhile collaborator Sirna Therapeutics, alleging that each company engaged in improper activities that undermined Protiva's key drug-delivery technology.

The legal maneuverings shed new light on a saga involving the RNAi drugs sector's two biggest players and allegations of fraud, theft of trade secrets, and breach of duty and contract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.